High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation
Rehman M, Vodret S, Braga L, Guarnaccia C, Celsi F, Rossetti G, Martinelli V, Battini T, Long C, Vukusic K, Kocijan T, Collesi C, Ring N, Skoko N, Giacca M, Del Sal G, Confalonieri M, Raspa M, Marcello A, Myers MP, Crovella S, Carloni P, Zacchigna S. High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation. JCI Insight 2019, 4: e123987. PMID: 30996132, PMCID: PMC6538355, DOI: 10.1172/jci.insight.123987.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsCalciumCell DifferentiationCells, CulturedDisease Models, AnimalDrug RepositioningEndoplasmic Reticulum StressFibrosisHaloperidolHumansIntravital MicroscopyLungMiceMyocardiumMyofibroblastsOptical ImagingPrimary Cell CultureReceptor, Notch1Receptors, sigmaRNA InterferenceRNA, Small InterferingSignal TransductionConceptsMyofibroblast activationSigma receptor 1Smooth muscle actinDifferent animal modelsTransforming Growth FactorDiscovery of haloperidolTumor-associated fibrosisMechanism of actionEndoplasmic reticulum stress responseFibrotic burdenAntifibrotic effectsAntifibrotic propertiesCommon antipsychotic drugsAntipsychotic drugsFibrotic processIntracellular calciumReticulum stress responseAnimal modelsMuscle actinFibrotic conditionsHaloperidolReceptor 1Growth factorContractile proteinsTherapeutic solutions